Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 11/20 | 0.48 |
| ▸ | SLC2A3 | P11169 | 11/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | BLK | P51451 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | STK3 | Q13188 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173524 | 1.00 | MEN1 (0.50) | MEN1KMT2ASLC2A1SLC2A3PRKD3 | |
| SCHEMBL27249099 | 0.93 | SLC2A1 (0.50) | MEN1KMT2ASLC2A1SLC2A3PRKD3 | |
| SCHEMBL31173657 | 0.93 | SLC2A1 (0.50) | MEN1KMT2ASLC2A1SLC2A3PRKD3 | |
| SCHEMBL31173666 | 0.91 | ROCK2 (0.49) | SLC2A1SLC2A3PRKD3METROCK2 | |
| SCHEMBL27248574 | 0.91 | ROCK2 (0.49) | SLC2A1SLC2A3PRKD3METROCK2 | |
| SCHEMBL27248597 | 0.90 | MEN1 (0.63) | MEN1KMT2ASLC2A1SLC2A3ROCK2 | |
| SCHEMBL27249085 | 0.90 | LMNA (0.52) | MEN1KMT2ASLC2A1SLC2A3PRKD3 | |
| SCHEMBL27248988 | 0.88 | ABCG2 (0.54) | SLC2A1SLC2A3PRKD3METROCK2 | |
| SCHEMBL31173534 | 0.87 | MEN1 (0.49) | MEN1KMT2ASLC2A1SLC2A3PRKD3 | |
| SCHEMBL27248867 | 0.87 | SLC2A1 (0.48) | SLC2A1SLC2A3PRKD3METROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | MEN1 1114/4885KMT2A 1406/4885SLC2A1 1/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | MEN1 1114/4885KMT2A 1406/4885SLC2A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.